News
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Chief financial officer Karsten Munk Knudsen said that the pharma giant's cash channel was key to regaining market share and ...
Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...
Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback